Pfizer Tivdak — Revenues: increased by 3.1% to $33.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $33.00M to $33.00M.
pfe_segment_tivdak_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.00M | $28.00M | $33.00M | $34.00M | $37.00M | $33.00M | $46.00M | $37.00M | $32.00M | $33.00M |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | — | +600.0% | +17.9% | +3.0% | +8.8% | -10.8% | +39.4% | -19.6% | -13.5% | +3.1% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +825.0% | +17.9% | +39.4% | +8.8% | -13.5% | +0.0% |